Niagen Bioscience, Inc. Common Stock (NAGE) is a publicly traded Healthcare sector company. As of May 21, 2026, NAGE trades at $3.73 with a market cap of $294.68M and a P/E ratio of 17.16. NAGE moved +2.18% today. Year to date, NAGE is -41.86%; over the trailing twelve months it is -65.15%. Its 52-week range spans $3.57 to $14.69. Analyst consensus is strong buy with an average price target of $11.25. Rallies surfaces NAGE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Niagen Bioscience Posts 30% Revenue Growth to $129.4M, Eyes 15% 2026 Outlook: Niagen Bioscience reported 2025 net sales rose 30% year-over-year to $129.4 million with net income doubling to $17.7 million, beating its forecast. The company ended the year with $64.8 million cash, zero debt, and projected 2026 revenue of $145 million (15% growth) while exploring potential acquisitions.
| Metric | Value |
|---|---|
| Price | $3.73 |
| Market Cap | $294.68M |
| P/E Ratio | 17.16 |
| EPS | $0.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.69 |
| 52-Week Low | $3.57 |
| Volume | 7 |
| Avg Volume | 0 |
| Revenue (TTM) | $129.42M |
| Net Income | $17.38M |
| Gross Margin | 64.28% |
4 analysts cover NAGE: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.25.